Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

A Correction to this paper has been published: https://doi.org/10.1038/s41416-021-01312-1

Saved in:
Bibliographic Details
Published inBritish journal of cancer Vol. 124; no. 10; p. 1746
Main Authors van Breeschoten, Jesper, Wouters, Michel W. J. M., Hilarius, Doranne L., Haanen, John B., Blank, Christian U., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., de Groot, Jan-Willem B., Hospers, Geke A. P., Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S., Suijkerbuijk, Karijn P. M., Blokx, Willeke A. M., ten Tije, Bert-Jan J., van der Veldt, Astrid A. M., Vreugdenhil, Art, Boers-Sonderen, Marye J., van den Eertwegh, Alfonsus J. M.
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 11.05.2021
Nature Publishing Group
Subjects
631/67/1813/1634
692/4028/67/1813/1634
692/699/67/1813/1634
Biomedical and Life Sciences
Biomedicine
Cancer Research
Correction
Drug Resistance
Epidemiology
Molecular Medicine
Oncology
Online AccessGet full text

Cover

More Information
Summary:A Correction to this paper has been published: https://doi.org/10.1038/s41416-021-01312-1
Bibliography:correction
SourceType-Other Sources-1
content type line 63
ObjectType-Correction/Retraction-1
ISSN:0007-0920
1532-1827
DOI:10.1038/s41416-021-01312-1